BR112018008025A2 - inibidores de pdk1 heterocíclicos para uso no trata-mento de câncer - Google Patents

inibidores de pdk1 heterocíclicos para uso no trata-mento de câncer

Info

Publication number
BR112018008025A2
BR112018008025A2 BR112018008025-0A BR112018008025A BR112018008025A2 BR 112018008025 A2 BR112018008025 A2 BR 112018008025A2 BR 112018008025 A BR112018008025 A BR 112018008025A BR 112018008025 A2 BR112018008025 A2 BR 112018008025A2
Authority
BR
Brazil
Prior art keywords
cancer treatment
heterocyclic
pdk1 inhibitors
inhibitors
pdk1
Prior art date
Application number
BR112018008025-0A
Other languages
English (en)
Portuguese (pt)
Inventor
K. HANSEN Stig
E. BINNERTS Minke
Original Assignee
Sunesis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals, Inc. filed Critical Sunesis Pharmaceuticals, Inc.
Publication of BR112018008025A2 publication Critical patent/BR112018008025A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112018008025-0A 2015-10-23 2016-10-21 inibidores de pdk1 heterocíclicos para uso no trata-mento de câncer BR112018008025A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562245606P 2015-10-23 2015-10-23
US62/245,606 2015-10-23
PCT/US2016/058255 WO2017070565A1 (en) 2015-10-23 2016-10-21 Heterocyclic pdk1 inhibitors for use to treat cancer

Publications (1)

Publication Number Publication Date
BR112018008025A2 true BR112018008025A2 (pt) 2018-10-23

Family

ID=57209945

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008025-0A BR112018008025A2 (pt) 2015-10-23 2016-10-21 inibidores de pdk1 heterocíclicos para uso no trata-mento de câncer

Country Status (14)

Country Link
US (3) US20190015410A1 (cg-RX-API-DMAC7.html)
EP (2) EP3763368A1 (cg-RX-API-DMAC7.html)
JP (1) JP7094879B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180101329A (cg-RX-API-DMAC7.html)
CN (1) CN108697699A (cg-RX-API-DMAC7.html)
AU (2) AU2016342352B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018008025A2 (cg-RX-API-DMAC7.html)
CA (1) CA3002907A1 (cg-RX-API-DMAC7.html)
DK (1) DK3364971T3 (cg-RX-API-DMAC7.html)
ES (1) ES2820770T3 (cg-RX-API-DMAC7.html)
MX (1) MX381727B (cg-RX-API-DMAC7.html)
PL (1) PL3364971T3 (cg-RX-API-DMAC7.html)
RU (1) RU2018118786A (cg-RX-API-DMAC7.html)
WO (1) WO2017070565A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114763326B (zh) * 2021-01-13 2026-01-02 南京宁丹新药技术股份有限公司 一类氨基酸酯衍生物及其用途
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2024040242A1 (en) * 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Combinations of pdk1 inhibitors and kinase inhibitors
WO2024040241A1 (en) 2022-08-19 2024-02-22 Viracta Therapeutics, Inc. Pharmaceutical formulations, processes for preparation, and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
DE102005061655A1 (de) * 2005-12-22 2007-06-28 Merck Patent Gmbh Diazepinone
PL2485731T4 (pl) 2009-10-06 2017-07-31 Millennium Pharmaceuticals, Inc. Związki heterocykliczne użyteczne jako inhibitory PDK1
WO2011067145A1 (en) * 2009-12-04 2011-06-09 Nerviano Medical Sciences S.R.L. Tricyclopyrazole derivatives
WO2019094779A1 (en) * 2017-11-09 2019-05-16 Sunesis Pharmaceuticals, Inc. Pharmaceutical formulations, processes for preparation, and methods of use

Also Published As

Publication number Publication date
KR20180101329A (ko) 2018-09-12
RU2018118786A (ru) 2019-11-26
PL3364971T3 (pl) 2021-05-31
US20240207258A1 (en) 2024-06-27
EP3364971A1 (en) 2018-08-29
US20230099829A1 (en) 2023-03-30
MX381727B (es) 2025-03-13
RU2018118786A3 (cg-RX-API-DMAC7.html) 2020-02-25
US20190015410A1 (en) 2019-01-17
AU2016342352A1 (en) 2018-05-10
EP3364971B1 (en) 2020-06-17
CN108697699A (zh) 2018-10-23
AU2016342352B2 (en) 2022-06-02
JP7094879B2 (ja) 2022-07-04
DK3364971T3 (da) 2020-09-21
ES2820770T3 (es) 2021-04-22
MX2018004977A (es) 2018-07-06
JP2018538244A (ja) 2018-12-27
EP3763368A1 (en) 2021-01-13
AU2022203204A1 (en) 2022-06-02
CA3002907A1 (en) 2017-04-27
WO2017070565A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
CO2018005369A2 (es) Inhibidores triazol de acc y usos de los mismos
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
MX2020011558A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
PH12019502379A1 (en) Pd-1/pd-l1 inhibitors
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
MX2017007629A (es) Compuestos inhibidores de bcl-xl que tienen una baja permeabilidad en las celulas y conjugados de anticuerpo-farmaco que los incluyen.
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
EP4236652A3 (en) Materials for organic electroluminescent devices
UY37018A (es) Inhibidores bicíclicos de pad4
MX2016012829A (es) Inhibidores de biaril cinasa.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
MX2019013645A (es) Inhibidores de quinasa y usos de los mismos.
PH12016500739A1 (en) Inhibitors of the fibrolast growth factor receptor
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
UY32529A (es) Compuestos heterocíclicos y su uso como inhibidores de la glucógeno sintetasa quinasa 3
ECSP17010481A (es) Novedosas pirimidinas 2,5-sustituidas
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
MX2016002924A (es) Inhibidores de cinasa a base de eter arilico.
CO2017001523A2 (es) Novedosas pirimidinas 2,5-sustituidas
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]